Protein Quality Control Holds the Key to Supercharging Cancer-Fighting T Cells

Cancer immunotherapy has transformed oncology, yet many patients fail to respond because their tumor-fighting T cells progressively lose function — a process called exhaustion. Understanding what separates resilient T cells from exhausted ones is one of the most pressing questions in cancer biology and has direct implications for improving immunotherapy.

Researchers at UC San Diego used proteomic and transcriptomic profiling to compare multiple T cell populations: tissue-resident memory T cells (TRM), progenitor-exhausted TIL, and terminally exhausted TIL. They identified proteostasis — the cellular machinery responsible for maintaining proper protein folding and clearance — as a key distinguishing feature. Specifically, three E3 ubiquitin ligases, NEURL3, RNF149, and WSB1, were significantly reduced in terminally exhausted TIL, leading to an accumulation of unfolded proteins even though the proteasome itself remained functional.

When the team enforced expression of these ligases in T cells, the results were striking. T cells preserved stem-like TCF1+ populations, which are associated with long-term immune memory and responsiveness. These engineered cells performed better in tumor environments and during chronic infection models. Conversely, deleting these ligases impaired TIL function and disrupted normal T cell differentiation even during acute infection.

Critically, restoring ligase expression rescued the unfolded protein burden in TIL and improved outcomes in preclinical immunotherapy models, suggesting this approach could translate into next-generation cell therapies such as CAR-T or TIL therapy.

The findings reframe T cell exhaustion not just as a transcriptional or epigenetic problem but as a proteostasis failure — a concept with broad implications for aging, chronic disease, and cancer. Caveats include that results are preclinical, and the summary is based on the abstract only.